Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."

TAVR is being used in more patients to treat severe aortic stenosis. However, according to a new commentary piece, SAVR is still the smartest treatment option for certain populations, including younger patients with bicuspid aortic valves.

SCAI President James B. Hermiller, Jr., MD, detailed the group's key policy concerns in 2025 and beyond in a new video interview. 

Older heart failure patients with no immediate family are especially vulnerable. Additional interventions may be necessary to reach these patients and provide the best care possible.

Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.

ACC President Christopher Kramer, MD, testified before a Congressional subcommittee to ask for federal funding to support a new law aimed at reducing sudden cardiac arrest deaths, and to support NIH research.

The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.

ACC Immediate Past President Cathie Biga spoke to Cardiovascular Business about some of the challenges healthcare faces in the wake of mass layoffs and significant funding cuts put in place by the Trump administration.